Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jing Hieng Ngu

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
World Journal of Gastrointestinal Pharmacology and Therapeutics|February 9, 2016
Clinical applications, limitations and future role of transient elastography in the management of liver diseasePik Eu Chang, George Boon-Bee Goh, Jing Hieng Ngu, et al.
Hepatology International|April 23, 2016
Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patientsNwe Ni Than, Doreen Koay Siew Ching, James Hodson, et al.
Hepatology (Baltimore, Md.)|April 17, 2024
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patientsYu Jun Wong, Vincent L Chen, Asim Abdulhamid, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2021
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCTSeng Gee Lim, Wei Lyn Yang, Jing Hieng Ngu, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2020
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)Seng Gee Lim, Wah Wah Phyo, Joanna Zhi Jie Ling, et al.
Antiviral Research|April 19, 2024
Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferonDaniel Q Huang, Liang Shen, Wah Wah Phyo, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
World Journal of Gastrointestinal Pharmacology and Therapeutics|February 9, 2016
Clinical applications, limitations and future role of transient elastography in the management of liver diseasePik Eu Chang, George Boon-Bee Goh, Jing Hieng Ngu, et al.
Hepatology International|April 23, 2016
Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patientsNwe Ni Than, Doreen Koay Siew Ching, James Hodson, et al.
Hepatology (Baltimore, Md.)|April 17, 2024
Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patientsYu Jun Wong, Vincent L Chen, Asim Abdulhamid, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2021
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCTSeng Gee Lim, Wei Lyn Yang, Jing Hieng Ngu, et al.
Alimentary Pharmacology & Therapeutics|November 7, 2020
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)Seng Gee Lim, Wah Wah Phyo, Joanna Zhi Jie Ling, et al.
Antiviral Research|April 19, 2024
Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferonDaniel Q Huang, Liang Shen, Wah Wah Phyo, et al.
Pageof 2